Abstract
Pharmacogenomics promises to help maximize efficacy and minimize adverse drug reactions. It could have a significant impact on the treatment of cardiovascular disease, the leading cause of death in the United States. The past decade has seen pharmacogenomics move from study of a candidate gene to genome-wide approaches, with the development of a series of pharmacogenetic tests. However, many barriers need to be overcome for cardiovascular pharmacogenomics to have its promised clinical impact.
Original language | English (US) |
---|---|
Pages (from-to) | 493-495 |
Number of pages | 3 |
Journal | Clinical pharmacology and therapeutics |
Volume | 90 |
Issue number | 4 |
DOIs | |
State | Published - Oct 2011 |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)